A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia,

Trial Profile

A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia,

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2012

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Therapeutic Use
  • Sponsors Karo Bio
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2009 Results will be presented at the 80th Annual Meeting of the American Thyroid Association (ATA), held September 23-27, 2009, Florida, US, according to a Karo Bio media release.
    • 30 Oct 2008 Top line data has been reported by Karo Bio in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top